Elsevier

Vaccine

Volume 30, Issue 2, 5 January 2012, Pages 103-104
Vaccine

Editorial
The re-emergence of measles in developed countries: Time to develop the next-generation measles vaccines?

https://doi.org/10.1016/j.vaccine.2011.11.085Get rights and content

Section snippets

Disclosures

Dr. Poland chairs data monitoring committees for non-measles vaccines being developed by Merck & Co. Dr. Jacobson also serves on a data monitoring committee as well as a safety review committee concerning non-measles vaccines produced by Merck & Co.

Acknowledgement

This work is supported in part by funding from the National Institutes of Health, AI-033144.

References (16)

  • I.H. Haralambieva et al.

    A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine

    Vaccine

    (2011 June)
  • Notes from the field: measles outbreak—Indiana, June–July 2011

    MMWR

    (2011)
  • Notes from the field: measles outbreak—Hennepin county, Minnesota, February–March 2011

    MMWR Morb Mortal Wkly Rep

    (2011)
  • UK Health Protection Agency

    Confirmed measles cases in England and Wales—An Update to End of May 2008

    (2008 May 31)
  • European Centre for Disease Prevention and Control. Epidemiological update on measles in EU and EEA/EFTA Member States....
  • World Health Organization. Measles Outbreaks in Europe. 4–21–2011;...
  • MMWR. Measles—United States, January–May 20, 2011; Report No....
  • International Society for Infectious Diseases. Measles Update 2011. 500, 2011;...
There are more references available in the full text version of this article.

Cited by (45)

  • Perceptions of the safety of vaccines and vaccine associated knowledge levels in Europe: A 2019 cross-sectional study in 28 countries

    2022, Preventive Medicine
    Citation Excerpt :

    Although globally vaccine hesitation is not the sole reason for these outbreaks, and perceived safety is not always the foundation of hesitancy, the issue is particularly relevant to European countries. The UK declared measles an endemic not long ago and other European countries are also experiencing increased cases (Poland and Jacobson, 2012; Public Health England, 2022). Italy has been suffering from severe measles outbreaks over the past ten years, in large part due to consistently inadequate uptake in the measles vaccination (Siani, 2019).

  • Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination

    2016, Vaccine
    Citation Excerpt :

    While insufficient vaccine coverage is a clear and major contributor to many outbreaks [7], both primary and secondary vaccine failures also play a role. In outbreaks in developed countries since 2000, many have involved previously immunized individuals [2,6,8–11]. Studies have demonstrated vaccine failure rates of 2–10% in individuals immunized with the recommended two doses of the measles vaccine [12–14].

  • Rubella seronegativity in antenatal screening - Is it influenced by the introduction of universal childhood rubella immunization?

    2015, Vaccine
    Citation Excerpt :

    Indeed, similar patterns were observed in Sweden [3], Israel [7,8], Poland [9], and Taiwan [10]. Regardless of the underlying mechanisms, this is a cause for concern as it could replicate the paradox of immunization against measles, which re-emerges as a serious threat with outbreaks occurring in developed countries without any issue in vaccine access, public health infrastructure, and health literacy, with 8.9% of healthy children immunized a mean of 7.4 years earlier lacked protective levels of antibody [47], and 30–100% of all reported measles cases occurred in previously immunized students [48]. Moreover, in subjects with documented vaccination, 48.1% and 51.9%, respectively showed a primary and secondary immune response, while primary vaccine failure was found in all 13 patients vaccinated prior to age 1 year, and in 43.5% and 12.5% of patients receiving one or two doses after their first birthdays [49].

View all citing articles on Scopus
View full text